EpiBiologics announced a $107 million Series B to advance its extracellular protein degradation platform and its lead bispecific degrader, EPI‑326, toward clinical testing. The round was led by GV and Johnson & Johnson’s venture arm, with participation from Novartis Venture Fund and others. EpiBiologics develops 'EpiTACs'—bispecific antibodies that tag cell‑surface proteins for lysosomal disposal; EPI‑326 targets tumor‑associated EGFR variants and will enter first‑in‑human trials in relapsed or refractory non‑small cell lung and head‑and‑neck cancers in 1H 2026. Management highlighted a favorable preclinical safety profile and the program’s potential for combinations with existing targeted therapies. Investors framed the raise as validation of targeted protein degradation applied to cell‑surface oncology targets, and the company signaled plans to disclose additional pipeline programs and combination strategies later this year.